These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24868139)

  • 1. The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1.
    Li J; Cui Y; Wang Q; Guo D; Pan X; Wang X; Bi H; Chen W; Liu Z; Zhao S
    Mol Vis; 2014; 20():649-60. PubMed ID: 24868139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Brown Seaweed Extract from
    Dörschmann P; Schmitt C; Bittkau KS; Neupane S; Synowitz M; Roider J; Alban S; Held-Feindt J; Klettner A
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33302412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM).
    Ayalasomayajula SP; Ashton P; Kompella UB
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):97-103. PubMed ID: 19284324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor induces VEGF expression via activation of the Wnt/β-catenin signaling pathway in ARPE-19 cells.
    Wang Y; Sang A; Zhu M; Zhang G; Guan H; Ji M; Chen H
    Mol Vis; 2016; 22():886-97. PubMed ID: 27499609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
    Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
    Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
    Du S; Wang S; Wu Q; Hu J; Li T
    Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E; Ayaz L; Kurt AH
    J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of IL-8 induced angiogenesis in uveal melanoma.
    Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
    Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
    Bahrami B; Shen W; Zhu L; Zhang T; Chang A; Gillies MC
    Clin Exp Ophthalmol; 2019 Nov; 47(8):1074-1081. PubMed ID: 31265210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of concentration of amyloid β (Aβ) on viability of cultured retinal pigment epithelial cells.
    Masuda N; Tsujinaka H; Hirai H; Yamashita M; Ueda T; Ogata N
    BMC Ophthalmol; 2019 Mar; 19(1):70. PubMed ID: 30849957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocrine impact of VEGF-A on uveal melanoma cells.
    Koch KR; Refaian N; Hos D; Schlereth SL; Bosch JJ; Cursiefen C; Heindl LM
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2697-704. PubMed ID: 24677103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.
    Golan S; Entin-Meer M; Semo Y; Maysel-Auslender S; Mezad-Koursh D; Keren G; Loewenstein A; Barak A
    BMC Res Notes; 2014 Sep; 7():617. PubMed ID: 25201034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.